Treatment of migraine
The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
1. A method for the acute treatment of migraine with or without aura in a patient with severe hepatic impairment, the method comprising orally administering 50 mg of ubrogepant to the patient, wherein the patient has a Child-Pugh score of Child-Pugh Class C, and wherein the patient's migraine is safely and effectively treated.
2. The method of claim 1 , comprising orally administering to the patient a second dose of 50 mg of ubrogepant at least 2 hours after the administration of the initial 50 mg of ubrogepant.
3. The method of claim 2 , wherein the second dose is administered between 2 and 24 hours after the administration of the initial 50 mg of ubrogepant.
4. The method of claim 1 , wherein the patient achieves freedom from at least one migraine symptom within 2 hours after the administration of said ubrogepant.